Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00356187 · ClinicalTrials.gov registry record · Phase 2

Beta Blockade in Critical Injury

A Phase 2 study, sponsored by Denver Health and Hospital Authority.

Terminated
Registry status
Phase 2
Development phase
15
Enrollment target

NCT00356187 is a Phase 2 study that was terminated before completion, run by Denver Health and Hospital Authority. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00356187, a Phase 2 study, was terminated before completion, sponsored by Denver Health and Hospital Authority.

TERMINATED
Registry status
Phase 2
Development phase
15 participants
Enrollment target

Study Summary

Critically injured patients endure a period of hypermetabolism/catabolism after being resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor wound healing, susceptibility to infection and long hospital stays. While there have been some data to suggest that hypermetabolism can be ameliorated in burn patients by beta blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of critically injured patients.

Interventions

  • DRUG Propranolol

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2006-02-15
Est. Completion 2009-01-31
Phase Phase 2

What the Registry Record Tells You About NCT00356187

The ClinicalTrials.gov registry entry for NCT00356187 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Propranolol is the first listed.

NCT00356187 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00356187 about?

NCT00356187 is a clinical study titled "Beta Blockade in Critical Injury". Critically injured patients endure a period of hypermetabolism/catabolism after being resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor wound healing, susceptibility to infection and long hospital stays. While there have been some data to suggest that hypermeta...

What is the current status of trial NCT00356187?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2006-02-15. Estimated completion is 2009-01-31.

What interventions are being tested in trial NCT00356187?

The interventions under investigation include: Propranolol (DRUG).

Who is sponsoring clinical trial NCT00356187?

This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.